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ABSTRACT

The presently-disclosed subject matter includes thermophilic
glucan phosphatase polypeptides. In some embodiments the
polypeptide includes non-native laforin polypeptides, or fragments and/or variants thereof, and in some instances the
polypeptide can alter the biophysical properties of starch in
vitro or in planta. The presently-disclosed subject matter also
includes isolated polynucleotides encoding the present
polypeptides, methods for processing starch by exposing
starch to the present polypeptides, and methods for making
the present polypeptides.
6 Claims, 7 Drawing Sheets
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THERMOPHILIC PHOSPHATASES AND
METHODS FOR PROCESSING STARCH
USING THE SAME

(1)

RELATED APPLICATION
This application claims priority from U.S. Provisional
Patent Application No. 61/825,440, filed May 20, 2013, the
entire disclosure of which is incorporated herein by this reference.
GOVERNMENT INTEREST
This invention was made with government support under
Grant Number R01NS070899 awarded the National Institutes of Health and Grant Number MCB1252345 awarded by
theNational Science Foundation. The government has certain
rights in the invention.
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TECHNICAL FIELD
The presently-disclosed subject matter relates to proteins
such as glucan phosphatases and methods of using the same to
process starch. In particular, embodiments of the presentlydisclosed subject matter relate to thermophilic phosphatase as
well as methods for processing starch utilizing at least a
thermophilic phosphatase and an amylase.
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INTRODUCTION
Starch is an important compound for many different purposes, including for food sources, beverages, the manufacture
of plastics, energy sources such as biofuels, industrial feedstocks, and so forth. For instance, starch from the seeds of
cereal crops and the tubers of potatoes and cassava accounts
for 50-80% of daily caloric intake. In the United States, over
20% of com starch is converted into ethanol for use as a
renewable biofuel, and starch also plays a central role in the
production of molecular hydrogen by some micro algae and
in algal oil production. Microalgal oil production is increased
by supplying starch to the microalgae so that they grow mixotrophically rather than autotrophically. Starch is also a cheap
and renewable industrial feedstock for producing paper, textiles, adhesives, plastics, and pharmaceuticals.
Starch is comprised of amylose and amylopectin, which
are both glucose polymers. Amylose, the minor component, is
a linear molecule comprised of glucose moieties linked
together by a-1,4-glycosidic bonds with very few branches.
Amylopectin, the major component, is comprised of glucose
linked together by a-1 ,4-glycosidic bonds with a-1 ,6-glycosidic branches occurring every 12-25 glucose moieties. The
branches in amylopectin are arranged in clusters at regular
intervals, resulting in a tree-like pattern. Within the clusters,
adjacent glucose chains form double helices and the clusters
organize into crystalline lamellae. The crystalline lamellae
make amylopectin, and thus starch, water-insoluble. This
insolubility renders the surface of starch inaccessible to most
enzymes, including the amylases that can break it down for
processing. The structures of amylopectin ( 1) and amy lase (2)
are shown below.
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Therefore, to utilize starch for subsequent processing,
starch-based feedstocks are generated by a three-phase
approach that utilizes physical, chemical, and enzymatic
modification (FIG. 1). The physical modification produces
high energy costs due to both milling the material and cyclically modulating the temperature between 50° C. to over 100°
C. to liquefy starch. In addition to physical modification,
large amounts of acids and bases are utilized to increase
enzymatic accessibility. Large quantities of these chemicals
are costly to purchase and companies also incur the cost of
disposing the hazardous waste. Finally, these processes
require relatively large amounts of recombinant a-amylase,
which cleave a-1,4-glycosidic linkages, to convert the complex sugar into fermentable glucose in these.
Over the last 25 years others have attempted to optimize
a-amylase catalytic efficiency, thermostability, and pH tolerance to increase starch processing techniques. These efforts
utilize a three-tiered approach of exploiting a-amylases' biological diversity, structure/function analysis, and directed
evolution. Despite advances in increased catalytic efficiency
as well as heat and pH tolerance, the amylases are still unable
to degrade starch without mechanical and chemical assistance. Thus, generating starch-feedstocks using known techniques still results in high costs and environmental concerns
related to feedstock chemical treatments.
Hence, there remains a need for compositions and methods
for processing starch that are relatively less expensive, more
efficient, and present fewer environmental concerns than
known compositions and methods.
BRIEF DESCRIPTION OF THE SEQUENCE
LISTING
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The following is a brief description of the Sequence Listing
that is attached hereto and is hereby incorporated by reference
in its entirety.
SEQ ID NO: 1 is a nucleic acid sequence encoding a
Cyanidioschyzon merolae laforin polypeptide of SEQ ID NO:
2;
SEQ ID NO: 2 is an amino acid sequence encoding a
Cyanidioschyzon merolae laforin polypeptide;
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SEQ ID NO: 3 is a nucleic acid sequence encoding a
Cyanidioschyzon merolae laforin polypeptide fragment of
SEQIDNO: 4;
SEQ ID NO: 4 is an amino acid sequence encoding a
Cyanidioschyzon merolae laforin polypeptide fragment.
SEQ ID NO: 5 is a nucleic acid sequence encoding a
Cyanidioschyzon merolae laforin polypeptide fragment of
SEQIDNO: 6;
SEQ ID NO: 6 is an amino acid sequence encoding a
Cyanidioschyzon merolae laforin polypeptide fragment.
SEQ ID NO: 7 is a nucleic acid sequence encoding a
Cyanidioschyzon merolae laforin polypeptide fragment of
SEQIDNO: 8;
SEQ ID NO: 8 is an amino acid sequence encoding a
Cyanidioschyzon merolae laforin polypeptide fragment.
SEQ ID NO: 9 is a nucleic acid sequence encoding a
Cyanidioschyzon merolae laforin polypeptide fragment of
SEQ ID NO: 10;
SEQ ID NO: 10 is an amino acid sequence encoding a
Cyanidioschyzon merolae laforin polypeptide fragment.

The present invention relates to novel, unique enzymes
(i.e., polypeptides) for processing starch. Processing starch
can include physically modifying the structure of a starch,
and in certain instances includes degrading the starch. The
polypeptides disclosed herein can also alter the biophysical
properties of starch and/or total biomass starch production.
For example, some embodiments of the present polypeptides
can increase total biomass starch production and/or degrade
starch in vitro, in planta, or both.
As used herein, the term "starch" is given its ordinary
meaning in the art. In this regard, starches are heterogeneous,
and their physicochemical properties, composition with
respect to amylose versus amylopectin, amount of phosphorylation, and molecular structure all can vary greatly depending on the source of the starch. These properties can also
affect starch gelatinization and viscosity, and thus impact
starch processing. Exemplary starch sources include, but are
not limited to, Arabidopsis, potato, corn, cassava, rice, wheat,
and the like.
As used herein, the terms "polypeptide", "protein", and
"peptide", which are used interchangeably herein, refer to a
polymer of the protein amino acids, or amino acid analogs,
regardless of its size or function. Although "protein" is often
used in reference to relatively large polypeptides, and "peptide" is often used in reference to small polypeptides, usage of
these terms in the art overlaps and varies. The term "polypeptide" as used herein refers to peptides, polypeptides, and
proteins, unless otherwise noted. The terms "protein",
"polypeptide", and "peptide" are used interchangeably herein
when referring to a gene product. Thus, exemplary polypeptides include gene products, naturally occurring proteins,
homologs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the foregoing.
In some embodiments the presently-disclosed polypeptides include thermophilic phosphatases and/or thermophilic
glucan phosphatases. Glucan phosphatases dephosphorylate
glucans in starch metabolism. In some instances, glucan
phosphatases dephosphorylate glucans so that starch can be
completely degraded by amylases.
In some embodiments the polypeptide is a laforin polypeptide, or a fragment and/or variant thereof. In some embodiments the laforin polypeptide can be a vertebrate laforin or a
vertebrate laforin ortholog. Exemplary vertebrate laforin
orthologs can include about 85%, about 90%, or about 95%
similarity with other vertebrate laforin at the amino acid level.
Furthermore, in some embodiments the polypeptide includes
a protozoan laforin, or a fragment and/or variant thereof. The
laforin can be based on laforin obtained from protozoa
including, but not limited to, tetrahymena thermophile, Eimeria tenella, Toxoplasma gondii, Paramecium tetraurelia,
Neospora caninum, and Cyanidioschyzon merolae. Exemplary protozoan laforin orthologs can include about 20% or
more, about 25% or more, about 30% or more, or about 35%
or more similarity with Homo sapien laforin (Hs-laforin) at
the amino acid level.
Certain plant species, such as single-cell algae Cyanidioschyzon merolae (C. merolae), include thermophilic
polypeptides (thermophile) that can process and degrade
native starch nnder harsh temperatures and extreme pH conditions in. For instance, C. merolae lives in acidic environments at temperatures of about 50 to about 75° C., living in
and aronnd thermal vents. The present inventors have found
that C. merolae includes laforin (hereinafter "Cm-laforin")
polypeptides that can enhance starch degradation by amylases and allow amylases to release more glucose. A full
length native wild-type protein sequence for Cm-laforin is
included herein (SEQ ID NO: 2). Embodiments of the pres-
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BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 includes a schematic showing a conventional
method for processing starch compared to a plant-based
starch processing method.
FIG. 2 includes a schematic showing the sequences of the
phosphatases of SEQ ID NOS: 2, 4, 6, 8, and 10 as well as
human laforin, SEX4, and LSF2.
FIG. 3 includes a plot showing the results of a glucan
phosphatase assay performed with human, Cyaniioschyzon
merolae (C. merolae), chicken, rat, and mouse laforin.
FIG. 4 includes Coomassie stained protein gel images
showing the expression and purification of different C. merolae laforin (Cm-laforin) fragments from E. coli.
FIG. SA includes a plot showing Cm-laforin phosphatase
activity utilizing a non-biologically relevant substrate pNPP
over a range from about 37° C. to about 75° C.
FIG. SB includes a plot showing Cm-laforin phosphatase
activity from about 3.0 pH to about 8.0 pH.
FIG. SC includes a plot showing SEX phosphatase activity
utilizing a non-biologically relevant substrate pNPP over a
range from about 37° C. to about 75° C.
FIG. SD includes a plot showing SEX4 phosphatase activity from about 3.0 pH to about 8.0 pH.
FIG. SE includes a plot showing the efficiency with which
Cm -laforin and Hs-laforin can remove phosphate from the C3
and C6 positions of a glucose ring.
FIG. 6 includes a plot showing that Cm-laforin increases
the degradation of starch via amylases (BAM3 and ISA3) in
the presence of the kinase GWD.
DETAILED DESCRIPTION OF EXEMPLARY
EMBODIMENTS
The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document. Modifications to embodiments described in this document, and
other embodiments, will be evident to those of ordinary skill
in the art after a study of the information provided in this
document. The information provided in this document, and
particularly the specific details of the described exemplary
embodiments, is provided primarily for clearness of understanding and no unnecessary limitations are to be understood
therefrom. In case of conflict, the specification of this document, including definitions, will control.
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ently-disclosed polypeptides include isolated and/or nonnaturally occurring fragments and/or variants of wild-type
laforin.
Accordingly, in some embodiments the polypeptide is a
thermophile. The term "thermophile" herein refers to characteristic of operating normally (i.e., is stable) at least at temperatures above about 40° C. In some embodiments the thermophile can operate at temperatures between about 40° C.
and about 85° C. For example, a "thermophilic polypeptide,"
"thermophile," or and the like refer to a polypeptide that can
function at least at temperatures above about 40° C., and a
"thermophilic organism" is an organism that can function at
least at temperatures above about 40° C. Some thermophiles
can also be stable at relatively lower temperatures. For
instance, some exemplary Cm-laforin polypeptides are stable
at temperatures of about 10° C. to about 75° C.
Additionally, in some embodiments the polypeptide can be
stable at non-neutral pH. In some embodiments the polypeptide can be stable at about 3.0 pH to about 8.0 pH. In specific
embodiments the polypeptide can be stable at about 3.0 pH,
4.0 pH, 5.0 pH, 6.0 pH, 7.0 pH, or 8.0 pH.
In some embodiments the polypeptide is a fragment of the
polypeptide including the sequence of SEQ ID NO: 2. The
terms "polypeptide fragment" or "fragment", when used in
reference to a reference polypeptide, refers to a polypeptide in
which amino acid residues are deleted as compared to the
reference polypeptide itself, but where the remaining amino
acid sequence is usually identical to the corresponding positions in the reference polypeptide. Such deletions can occur at
the amino-terminus, carboxy-terminus of the reference
polypeptide, or alternatively both. A fragment can also be a
"functional fragment," in which case the fragment retains
some or all of the activity of the reference polypeptide as
described herein.
In some embodiments the polypeptide can comprise the
sequence of SEQ ID NO: 2 and can include about 267, 268,
269,270,271,272,273,274,275,276,277,278,279,280,
281,282,283,284,285,286,287,288,289,290,291,292,
293,294,295,296,297,298,299,300,301,302,303,304,
305,306,307,308,309,310,311,312,313,314,315,316,
317,318,319,320,321,322,323,324,325,326,327,328,
329,330,331,332,333,334,335,336,337,338,339,340,
341,342,343,344,345,346,347,348,349,350,351,352,
353,354,355,356,357,358,359,360,361,362,363,364,
365,366,367,368,369,370,371,372,373,374,375,376,
377,378,379,380,381,382,383,384,385,386,387,388,
389,390,391,392,393,394,395,396,397,398,399,400,
401,402,403,404,405,406,407,408,409,410,411,412,
413,414,415,416,417,418,419,420,421,422,423,424,
425,426,427,428,429,430,431,432,433,434,435,436,
437,438,439,440,441,442,443,444,445,446,447,448,
449,450,451,452,453,454,455,456,457,458,459,460,
461,462,463,464,465,466,467,468,469,470,471,472,
473,474,475,476,477,478,479,480,481,482,483,484,
485,486,487,488,489,490,491,492,493,494,495,496,
497,498,499,500,501,502,503,504,505,506,507,508,
509, 510,511,512, 513, 514,515, 516, 517,518, 519, 520,
521, 522, 523, 524, 525, 526, 527, 528, 529, 530, or 531
amino acid residues. In specific embodiments the polypeptide
fragments include about 1 to about 266 amino acid residues
deleted from theN-terminus of the polypeptide, including
polypeptide fragments having about 1 to about 266 amino
acid residues deleted from theN-terminus immediately following the start methionine (M) amino acid.
As described herein, the presently disclosed subject matter
also include variants of the presently-disclosed polypeptides.
The term "variant" refers to an amino acid sequence that is

different from the reference polypeptide by one or more
amino acids, e.g., one or more amino acid substitutions. For
example a glucan phosphate polypeptide variant differs from
wild-type glucan phosphatase by one or more amino acid
substitutions, i.e., mutations. In this regard, polypeptide variants comprising combinations of two or more mutations can
respectively be referred to as double mutants, triple mutants,
and so forth. It will be recognized that certain mutations can
result in a notable change in function of a polypeptide, while
other mutations will result in little to no notable change in
function of the polypeptide.
In some embodiment the present polypeptides include constituents that share at least 75% homology with a wild type
polypeptide. In some embodiments the polypeptides share at
least 85% homology with the wild type polypeptide. In some
embodiments the polypeptides share at least 90% homology
with the wild type polypeptide. In some embodiments the
polypeptides share at least 95% homology with the wild type
polypeptide. The wild type polypeptide can include the nonnative Cm-laforin polypeptide having the sequence of SEQ
IDNO: 2.
"Percent identity," or "percent homology" when used
herein to describe to an amino acid sequence or a nucleic acid
sequence, relative to a reference sequence, can be determined
using the formula described by Karlin and Altschul (Proc.
Nat!. Acad. Sci. USA 87: 2264-2268, 1990, modified as in
Proc. Nat!. Acad. Sci. USA 90:5873-5877, 1993). Such a
formula is incorporated into the basic local alignment search
tool (BLAST) programs of Altschul eta!. (J. Mol. Bioi. 215:
403-410, 1990). [BLAST nucleotide searches are performed
with the NBLAST program, score+100, wordlength=12, to
obtain nucleotide sequences homologous to a nucleic acid
molecule of the invention. BLAST protein searches are performed with the XBLAST program, score=50, word
length=3, to obtain amino acid sequences homologous to a
reference polypeptide (e.g., SEQ ID NO: X). To obtain
gapped alignments for comparison purposes, Gapped
BLAST is utilized as described in Altschul, et a!. (Nucleic
Acids Res. 25: 3389-3402, 1997). When utilizing BLAST
and Gapped BLAST programs, the default parameters of the
respective programs (e.g., XBLAST and NBLAST) are used.
See http://www.ncbi.nlm.nik.gov, and reference is made to
the most recent version of the programs that are available as of
Jul. 19, 2012.
In one embodiment the polypeptide comprises the
sequence of SEQ ID NO: 4. In another embodiment the
polypeptide comprises a fragment, a variant, or both a fragment and variant of SEQ ID NO: 4. In another embodiment
the polypeptide comprises the sequence of SEQ ID NO: 6. In
another embodiment the polypeptide comprises a fragment, a
variant, or both a fragment and variant of SEQ ID NO: 6. In
another embodiment the polypeptide comprises the sequence
of SEQ ID NO: 8. In another embodiment the polypeptide
comprises a fragment, a variant, or both a fragment and variant of SEQ ID NO: 8. In another embodiment the polypeptide
comprises the sequence of SEQ ID NO: 10. In another
embodiment the polypeptide comprises a fragment, a variant,
or both a fragment and variant of SEQ ID NO: 10.
The presently-disclosed subject matter also includes isolated polynucleotides that encode any of the presently-disclosed polypeptides. The terms "nucleotide," "polynucleotide," "nucleic acid," and "nucleic acid sequence" refer to
deoxyribonucleotides or ribonucleotides and polymers
thereof in either single or double stranded form. Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar
binding properties as the reference nucleic acid and are
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metabolized in a manner similar to naturally occurring nucleotides. The terms also include compounds only comprising
the coding regions, or exons, of a particular DNA sequence.
The terms are therefore inclusive of eDNA molecules.
The term "isolated", when used in the context of an isolated
polynucleotide or an isolated polypeptide, is a polynucleotide
or polypeptide that, by the hand of man, exists apart from its
native environment and is therefore not a product of nature.
An isolated polynucleotide or polypeptide can exist in a purified form or can exist in a non-native environment such as, for
example, in a transgenic host cell. Unless otherwise indicated, all polypeptides and polynucleotides described herein
include isolated forms thereof even where not explicitly
recited. Thus, unless stated otherwise, all the polypeptide and
polynucleotide described herein can be modified by the term
isolated.
In some embodiments the polynucleotides encode a thermophilic phosphatase, laforin polypeptide, and/or a
Cm-laforin polypeptide. In other embodiments the polynucleotide includes the sequence of SEQ ID NO: 1, and the
polynucleotide encodes the polypeptide including the
sequence of SEQ ID NO: 2. In other embodiments the polynucleotide encodes a fragment and/or a variant of the
polypeptide including the sequence of SEQ ID NO: 2.
As before, the term "polynucleotide fragment" or the like
can refer to a polynucleotide in which nucleic acids are
deleted as compared to the reference polynucleotide itself,
but where the remaining nucleic acid sequence is usually
identical to the corresponding positions in the reference polynucleotide. Such deletions can occur at any location of the
sequence. In some embodiments the polynucleotide includes
a fragment of the isolated polynucleotide having the sequence
of SEQ ID NO: 1. In some embodiments the polynucleotide
fragment includes about 800, 900, 1000, 1100, 1200, 1300,
1400, 1500, or more nucleotides, and in some embodiments
the polynucleotide fragment includes about 801 to about
1596 nucleotides.
The term "variant" in reference to a polynucleotide can
refer to a polynucleotide that is different from the reference
polynucleotide by one or more nucleic acids. In this regard,
some polynucleotide variants have been codon optimized
relative to a reference polynucleotide, and the polynucleotide
variant can produce polypeptide more effectively in certain
organisms relative to the reference polynucleotide. For
instance, in some embodiments a polynucleotide that
includes the sequence of SEQ ID NOS: 3, 4, 5, or 9 expresses,
respectively, a polypeptide that includes the sequence of SEQ
ID NOS: 4, 6, 8, or 10 more effectively (e.g., higher purity) in
E. coli cells when compared to the polynucleotide having the
sequence of SEQ ID NO: 1. In this respect, a polynucleotide
variant can have a different sequence than a reference polynucleotide without necessarily expressing a polypeptide that
includes amino acid mutations relative to the reference
polypeptide.
Unless otherwise indicated, a particular nucleic acid
sequence also implicitly encompasses conservatively modified versions thereof (e.g., degenerate codon substitutions)
and complementary sequences and as well as the sequence
explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the
third position of one or more selected (or all) codons is substituted with mixed base and/or deoxyinosine residues
(Batzer eta!. (1991) Nucleic Acid Res 19:5081; Ohtsuka eta!.
(1985) J Bioi Chern 260:2605 2608; Rossolini eta!. (1994)
Mol Cell Probes 8:91 98). Thus, the term polynucleotide
includes both deoxyribonucleic acid (DNA) and ribonucleic

acid, and therefore the term polynucleotide specifically
includes complementary DNA as used herein.
In some embodiments the polynucleotide includes the
nucleotide sequence of SEQ ID NO: 3. In some embodiments
the polynucleotide includes the nucleotide sequence of SEQ
ID NO: 5. In some embodiments the polynucleotide includes
the nucleotide sequence of SEQ ID NO: 7. In some embodiments the polynucleotide includes the nucleotide sequence of
SEQ ID NO: 9.
The presently-disclosed subject matter further includes a
composition comprising starch, wherein the starch is from a
plant expressing one of the polypeptides described herein. In
some embodiments the polypeptide includes a thermophilic
glucan phosphatase polypeptide. In some embodiments the
polypeptides includes a laforin polypeptide, such as a Cmlaforin polypeptide. As discussed herein, organisms expressing the present polypeptides can produce starch with altered
biophysical properties, which can be beneficial for manufacturing processes in various industries, including food, beverage, confectionary, plastic, paper, building, energy, textile,
agriculture, and pharmaceutical industries.
The presently-disclosed subject matter further includes
methods for processing starch, wherein processing can
include degrading starch to smaller polysaccharides and/or
monosaccharides. In some embodiments the methods for processing starch comprise providing a starch, exposing the
starch to a thermophilic glucan phosphatase, and collecting
the starch that has been exposed to the thermophilic glucan
phosphatase. In some embodiments the present polypeptides
can be used in a method for processing starch that does not
require harsh acids and harsh bases. Thus, the present methods can be more cost-effective and have a smaller environmental impact relative to known methods.
The term "providing" as used herein to refer to delivering,
obtaining, procuring, or the like a substance. For instance, a
polypeptide, a starch, or both can be provided by any means.
In some embodiments the polypeptide is provided in an isolated form that can be exposed directly to a starch. In other
embodiments an organism expresses the polypeptide, and the
polypeptide is thereby provided by the organism. Likewise,
starch can be provided by itself or can be provided within a
plant.
In some embodiments the exposing step occurs within a
plant. That is, a plant can express a thermophilic glucan
phosphatase, and the thermophilic glucan phosphatase can be
exposed to starch within the plant. On the other hand, in
industrial applications a thermophilic glucan phosphatase
can be provided in an isolated form, and can be exposed to a
starch by mixing the two components in a container.
The term "collecting" is used herein to refer to any process
or method where starch is used, obtained, cultivated,
ingested, or the like. For example, in some embodiments
starch is collected by harvesting a plant that comprises starch
and processing the plant in order to obtain starch or other
sugars derived therefrom. In some embodiments, collecting
refers to ingesting a plant that comprises a thermophilic glucan phosphatase. In other embodiments collecting refers to
collecting starch that has been processed in a container with a
thermophilic glucan phosphatase.
The presently-described starch processing methods do not
suffer from the inability of amylases to access starch's water
insoluble surface. Amylases degrade starch to maltose and
glucose, but despite industry's 25 years of optimizing amylase to work under extreme conditions, amylase cannot
degrade its own starch. In order to solubilize starch and to
make it accessible to amylase, milling, extreme heat and acids
and bases are required. One recent improved method for
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processing starch is described in U.S. Provisional patent
application Ser. No. 13/928,160, which is incorporated herein
by reference, and which describes non-thermophilic glucan
phosphatase variants for starch dephosphorylation.
However, in order to overcome problems in the art, the
present inventors discovered that use of the present polypeptides allows the starch to be processed without the milling and
chemical treatments that are typically required. Thus, in some
instances the present polypeptides can make a starch accessible to amylases for processing. The present methods can
utilize polypeptides that include a thermophilic glucan phosphatase, such as laforin and the like. In specific embodiments
the thermophilic glucan phosphatase includes the sequence of
SEQ ID NO: 2, or a fragment and/or variant thereof.
Some methods further comprise exposing the starch to a
kinase, an amylase, or both before the collecting step. Some
embodied methods comprise a three-step exposing step
wherein the starch is sequentially exposed to a thermophilic
phosphatase, a kinase, and an amylase. In some embodied
methods glucan dikinases phosphorylate the outer starch surface and solubilize the outer surface allowing amylases to
bind and degrade starch, and glucan phosphatases release
phosphate and reset the cycle so that amylase-directed degradation can continue past the phosphate. Prior to the present
method, no known method used a combination of a thermophilic phosphatase, a kinase, and an amylase to process
starch. Instead, prior to the present invention, harsh acids and
bases were required to process starches. Accordingly, the
present methods that use a one or a combination of one or
more different polypeptides are superior to prior know methods for processing starch.
In some embodiments of the present methods, the polypeptides are thermophiles and are capable of functioning under
extreme conditions. For instance, Cm-laforin maintains its
activity from about 37° C. to about 75° C. and under a wide
range of pH conditions, including about 3.0 pH to about 8.0
pH. Additionally, Cm-laforin has a relatively high specific
activity and is relatively efficient at removing phosphate from
the C3 and C6 position of starch compared to human laforin.
Lastly, Cm-laforin can increase amylase-directed degradation of starch.
The presently-disclosed subject matter also includes methods for making an isolated polypeptide. In some embodiments the method comprises providing a cell that includes at
least one of the presently-described polynucleotides, culturing the cell under conditions that permit the cell to produce a
polypeptide encoded by the polynucleotide, and collecting
the polypeptide. The cell can naturally include the polynucleotide or the polynucleotide can be introduced to the cell by
known methods. For instance, a vector can be utilized to
introduce an embodiment of the present polynucleotides to
the cell.
The cell is not particularly limited except that it must be
capable of producing the polypeptide encoded by the polynucleotide. In some embodiments the polynucleotides can be
sequence optimized for the production of a polypeptide in a
particular cell, such as E. coli cells. The polypeptide produced
by the cell can be collected by known means, thereby providing the isolated polypeptide.

gathered at various times during the course of development
and experimentation related to the presently-disclosed subject matter.
Example 1
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EXAMPLES
The presently -disclosed subject matter is further illustrated
by the following specific but non-limiting examples. Some
examples are prophetic. Some of the following examples may
include compilations of data that are representative of data

This Example describes the identification, cloning strategies, and purification of Cm-laforin polypeptides.
Laforin genes were identified in six protozoan genomes:
Tetrahymena thermophile, Eimeria tenella, Toxoplasma gondii, Paramecium tetraurelia, Neospora caninum, and Cyanidioschyzon merolae. While the vertebrate laforin orthologs
are similar, the protozoan laforin orthologs are about 20% to
about 35% identical to Hs-laforin. Furthermore, some of
these organisms live in extreme envirouments and likely have
enzymes that function under harsh conditions. For example,
the single-cell red algae C. merolae lives in highly acidic
environments (i.e., pH<2) at temperatures of about 45° C. to
about 60° C.
Five of the protozoan laforin orthologs were cloned to
identify a laforin ortholog that was amenable to in vitro
manipulation. To define the optimal constructs for recombinant protein expression, laforin primary sequences were analyzed from multiple species using a similar strategy that was
successful for SEX4 (VanderKooi eta!., 201 0). The strategy
was to predict domain boundaries, secondary structure,
regions of disorder, and regions of hydrophobicity for the
polypeptides. Based on these data, the full-length laforin gene
was cloned as well as multiple fragments (i.e., truncations)
that remove the amino- and/or carboxy-terminus of the protein.
In the case of Cm-laforin, thedata, four Cm-laforin fragments were cloned into multiple bacterial expression vectors,
including Met27 (truncates first 26 amino acids), a codon
optimized for Ser157, a codon optimized for Gly258, and a
codon optimized for Arg267. Cm-laforin proteins that were
over 99% pure were expressed and purified were produced by
tranforming BL21-CodonPlus Escherichia coli cells (Stratagene, La Jolla, Calif.) with expression vector. Cells were
grown at 37° C. in 2xYT to an O.D.600 of0.6-0.8, placed in
ice for 20 minutes, were induced with 1 mM isopropyl ~-Dthiogalactoside (IPTG), were grown at 16° C. for about 16
hours, and were harvested by centrifugation. Cells were lysed
in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, and 2 mM
dithiothreitol (DTT), centrifuged, and the proteins were purified using a Profinia IMAC column with Ni2+ beads (BioRad, Hercules, Calif.) with a Profinia protein purification
system (Bio-Rad). Polypeptides were eluted in lysis buffer
containing 300 mM imidazole. Lastly, polypeptide was purified to homogeneity using a HiLoad 26/60 Superdex 200 size
exclusion column (General Electric, Schenectady, N.Y.)
(FIG. 4).
About 25 mg of soluble Cm-laforin per liter of E. coli cells
was purified. The Cm-laforin was capable ofbeing purified to
18 mg/ml, and this polypeptide was stable at 4 o C. for over 1
week. Given the relatively high purity that was attained, Cmlaforin was selected for further analysis.

65

This Example describes the cloning and identification of
vertebrate laforin orthologs.
A total of seven vertebrate laforin orthologs that all
robustly express in E. coli were identified, but only enough
protein was purified to perform in vitro assays due to protein
aggregation and precipitation. The vertebrate laforin
orthologs were more than 85% similar at the amino acid level.
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To test the glucan phosphatase activity of Cm-laforin, an
assay based on the complex formation of malachite green
with phospho-molybdate was implemented to measure inorganic phosphate release.
The glucan phosphatase assays against amylopectin, as
determined via released free phosphate by malachite green
detection, were performed as previously described with the
following modifications (Sherwood, 2013). Reactions were
performed in 20 f.LL, reactions, containing 1x phosphatase
buffer (0.1M sodium acetate, 0.05 M bis-Tris, 0.05 M TrisHCl, pH 7 .0, and 2 mM DTT), 100-1000 ng protein, and 45 flg
amylopectin. Amylopectin was solubilized using the Roach
method (Wang, 2004 ). The reaction was stopped by the addition of 20 f.LL, of 100 mM N-ethylmaleamide and 80 f.LL, of
malachite green reagent. Absorbance was measured at 620 m.
The assay was performed with each protein six times or more
to determine specific activity. Using this assay, it was found
that Cm-laforin possessed nearly twice the specific activity of
human-laforin, rat-laforin, or mouse-laforin (FIG. 3).

unincorporated 33P had been removed. These products were
utilized as substrates in dephosphorylation assays with Cmlaforin or human laforin.
In both the C6-33P- and C3-33P-labeleled cases, the starch
granules were phosphorylated at both positions; however, the
33P-label was located at only one or the other position. 33 P~-ATP was obtained from Hartmann Analytic (Braunschweig, Germany). 150 ng of recombinant proteins were incubated in dephosphorylation buffer (100 mM sodium acetate,
50 mM bis-Tris, 50 mM Tris-HCl, pH 6.5, 0.05% [v/v] Triton
X-100, 1 fld/flL [w/v] BSA, and 2 mM DTT) with the C6- or
C3-prelabeled starch (4 mg/mL) in a final volume of 150 f.LL
on a rotating wheel for 5 min at 25° C. The reaction was
terminated by the addition of 50 f.LL ofl 0% SDS. The reaction
tubes were then centrifuged at 13,000 rpm for 5 min to pellet
the starch. 33P release into 150 f.LL of supernatant was determined using a 1900 TR liquid scintillation counter (Packard
Elmer, Waltham, Mass.). The assay was performed with each
protein six times to determine specific activity (FIG. SE).
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Example 5

This Example describes procedures conducted to characterize the thermophilic activity ofCm-laforin polypeptides.
To observe generic phosphatase activity, a phosphatase
assay using the exogenous substrate para-nitrophenyl phosphate (pNPP) was implemented. Most DSPs can cleave
pNPP, and this cleavage results in a colorimetric change.
Since C. merolae is a thermophile, the phopshatase activity of
Cm-laforin was observed under a variety of temperatures and
pH conditions.
Previously-described phosphatase assays using pNPP
were performed with the following modifications (Sherwood,
2013; Gentry, 2007). Hydrolysis of pNPP was performed in
50 flL, reactions, containing 1x phosphatase buffer (0.1M
sodium acetate, 0.05 M bis-Tris, 0.05 M Tris-HCl, and 2 mM
DTT) at pH 3-8, 50 mM pNPP, and 1 flg of enzyme at 37-75°
C. for 15 minutes. The reaction was terminated by the addition of 200 f.LL of 0.25 M NaOH, and absorbance was measured at 410 nm. The assay was performed with each protein
six times or more to determine specific activity.
As shown in FIG. SA, Cm-laforin maintained its activity
from 37° C.-80° C. In addition, Cm-laforin was active over a
wide array of pH conditions from about 3.0 pH to about 8.0
pH (FIG. SB). On the other hand, SEX4 had a significantly
lower specific activity against pNPP, and SEX4 did not maintain its activity over a wide-range of temperature or pH conditions (FIGS. SC and SD).

This Example describes the Cm-laforin's ability to
enhance starch degradation to a higher degree than SEX4.
Native Arabidopsis starch was treated with combinations
ofBeta-amylase3 (BAM3) (sweet potato, Sigma A7005, St.
Louis, Mo.), isoamylase3 (ISA3) (Pseudomonas sp. Sigma
15284), GWD, and SEX4 or Cm-laforin. The total volume of
the assays were 200 ul and consisted of30 mM HEPES-KOH,
pH 7.5, 5 mM MgC1 2 , 5 mM CaC1 2 , 1 mMATP, 2.5 mg starch,
+1-1 ul stock concentration BAM, +1-1.5 ul1:50 stock dilution ISA, +1-4.5 ug GWD, +1-4.5 ug SEX4, and +1-4.5 ug
laforin. The samples were incubated for 90 minutes with
gentle agitation at room temperature. A 1.5 minute spin at
15,000 RPM was performed and the supernatant was collected, followed by another spin at 15,000 RPM for 5 minutes
to remove any residual starch. Any remaining oligosaccharides were hydrolyzed, and glucose content in the supernatant
was quantified using the Boehringer Mannheim assay kit
(10716251035; Ingelheim am Rhein, Germany) per manufacturer's protocol.
As shown in FIG. 6, ~-amylases (BAM) and isoamylases
(I SA) were responsible for degrading starch into glucose and
maltose in planta. Phosphate-free starch was isolated from
gwd/pwd deficient Arabidopsis plants and it was demonstrated that the activity of BAM3 and ISA3 are markedly
enhanced in vitro when starch is phosphorylated by the glucan dikinase GWD.
Furthermore, the hydrolysis activity of BAMs and ISA in
combination with GWD was observed in the presence and
absence of SEX4 and Cm-laforin. The activity ofBAM3 and
ISA3 increased in the presence of SEX4, and increased further in the presence of Cm-laforin (FIG. 6).
While the terms used herein are believed to be well understood by one of ordinary skill in the art, the definitions set
forth herein are provided to facilitate explanation of the presently-disclosed subject matter.
Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood
by one of ordinary skill in the art to which the presentlydisclosed subject matter belongs. Although any methods,
devices, and materials similar or equivalent to those described
herein can be used in the practice or testing of the presentlydisclosed subject matter, representative methods, devices,
and materials are now described.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this

Example 4
This Example describes procedures that measured the
position of the phosphate that is released off of glucose within
starch by Cm-laforin.
Phosphate release from 33P-lableled starch granules was
performed as previously described with the following variations (Kotting, 2009). Phosphate-free starch granules were
isolated from the Arabidopsis sex1-3 mutant. C6-33P-labeleled starch was generated by phosphorylating the starch
with 33 P-~-ATP at the C6-position by GWD followed by
washing nntil all unincorporated 33P had been removed, and
non-radio-labeled ATP was added with PWD to phosphorylate the C3 position followed by dialyzing and precipitating
out the ATP and PWD. C3-33P-labeled starch was generated
by phosphorylating the starch with unlabeled ATP at the
C6-position by GWD followed by phosphorylation with 33 P~R-ATP at the C3-position by PWD and washing until all
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application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and claims
are approximations that can vary depending upon the desired
properties sought to be obtained by the presently-disclosed
subject matter.
As used herein, the term "about," when referring to a value
or to an amount of mass, weight, time, volume, concentration
or percentage is meant to encompass variations of in some
embodiments ±50%, in some embodiments ±40%, in some
embodiments ±30%, in some embodiments ±20%, in some
embodiments ±10%, in some embodiments ±5%, in some
embodiments ±1 %, in some embodiments ±0.5%, and in
some embodiments ±0.1% from the specified amount, as such
variations are appropriate to perform the disclosed method.
As used herein, ranges can be expressed as from "about"
one particular value, and/or to "about" another particular
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
as "about" that particular value in addition to the value itself.
For example, if the value "10" is disclosed, then "about 10" is
also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, ifl 0 and
15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
Throughout this document, various references are mentioned. All such references, including those listed below, are
incorporated herein by reference.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 10
<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 1
LENGTH, 1599
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, C. merolae laforin full-length

<400> SEQUENCE, 1
atggcgcgta tacgaacatc ggatcgccgg aacacaaacg accaggcagg ctcggaaagc

60

cggcatcggg tgccgtcgat ggcaagagcg ccagctgctg attcgtctgg tgcgcagtca

120

acaccagccg cacggcgtgc ttccgaggga gtctctgtag ctgagcctcc gtcaaagcca

180

gctgctgatt cgtctggtgc gcagtcaaca ccagccgcac ggcgtgcttc cgagggagtc

240

tctgtagctg ggcctccatc aaagccagct gccgattcgt ctggtgcgca gtcaacacca

300

gccgcacggt ttgcatccga gggtgtctct gtacctgagc ctccgtcaaa gccagctgct

360

gattcgtctg gtgcgcagtc aacaccagcc gcacggggtg cttccgagga tatctctgta

420
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cctgggcctc cttcagacat tgcggacacg atctcaaaga atgatcgaag cgtaaccccg

480

acgattccga ctttattccg cgtctactgc cacacggagt ttggcgatgc tgtcgtcgcc

540

gctggtagtc acgacaaatt gggcaactgg gagcccgcga aagcgctccg gctccgtcat

600

caatgccaag tggatacacc gttccgtgac tgctgggaag gcgaggtaga ccttgtaccc

660

gaaacaagct tcgagttcaa attcgtgcgt cttataggcg gagatccgca gcgtgcgctc

720

tgggaaaccg gacccaaccg aagagccgtg atccagagaa actcgaagga cggctgcctg

780

attgaagtgg aatgggagcg tacgcgtgtg ctgttctcaa tatactatcc taccaaagag

840

aagcagcatc tctgtgtcac tggcgatctt ccggaaatcg gtcggtgggt agaaccgggt

900

ccagtaccca tggccctctc aactactgag gagcgtttgg aaacaggagg caagggccga

960

cgttggtcct tgacggtttc agtgccatcc acggtgggca aattcgccta tcgctatgtg

1020

ctagtcgacg ataaccgcca gcaaacgatc tgggaacgag aaccgaatcg ctatgcaaca

1080

ctagaacgag cggtgaacgg gcgcctcgaa tgtttcgatg caaattttgt cgcttcgtta

1140

gaatttgatg aaatatgtcc ggacatttac atagggccct acccacaaac tccagagcat

1200

gtcgaaatga tgcatgaggc ggggattacg gctgttttga atttacagac cgatgaggac

1260

tttgcacacc gcagtattcc ctggtcgacg ctgatggaga catatacagc actagagatg

1320

caagtcatcc gttgtccgat tccggatttt aatgcggagg cgctcatgca gttgcttccg

1380

gatgccgtac gcgctcttga tgcggcgctc aaggcgaagc gcgtcgtcta cgtgcactgt

1440

accgcaggaa tgggtcgagc gcccgctgta gttgtcgcct acctcgtgtg gcgccgcggc

1500

atgacgctgg aggatgcctt gtcgcacgtt aaagcacgtc gtgctgtggc cgcgccgaat

1560

gtcaccgtat tggaaaaggt tcttcgtaat cccttgtga

1599

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH, 532
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, C. merolae laforin full-length polypeptide

<400> SEQUENCE, 2
Met Ala Arg Ile Arg Thr Ser Asp Arg Arg Asn Thr Asn Asp Gln Ala
1
5
10
15
Gly Ser Glu Ser Arg His Arg Val Pro Ser Met Ala Arg Ala Pro Ala
20
25
30
Ala Asp Ser Ser Gly Ala Gln Ser Thr Pro Ala Ala Arg Arg Ala Ser
35
40
45
Glu Gly Val Ser Val Ala Glu Pro Pro Ser Lys Pro Ala Ala Asp Ser
50
55
60
Ser Gly Ala Gln Ser Thr Pro Ala Ala Arg Arg Ala Ser Glu Gly Val
65
70
75
80
Ser Val Ala Gly Pro Pro Ser Lys Pro Ala Ala Asp Ser Ser Gly Ala
85
90
95
Gln Ser Thr Pro Ala Ala Arg Phe Ala Ser Glu Gly Val Ser Val Pro
100
105
110
Glu Pro Pro Ser Lys Pro Ala Ala Asp Ser Ser Gly Ala Gln Ser Thr
115
120
125
Pro Ala Ala Arg Gly Ala Ser Glu Asp Ile Ser Val Pro Gly Pro Pro
130
135
140
Ser Asp Ile Ala Asp Thr Ile Ser Lys Asn Asp Arg Ser Val Thr Pro

US 9,222,114 B1
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145

150

155

160

Thr Ile Pro Thr Leu Phe Arg Val Tyr Cys His Thr Glu Phe Gly Asp
165
170
175
Ala Val Val Ala Ala Gly Ser His Asp Lys Leu Gly Asn Trp Glu Pro
180
185
190
Ala Lys Ala Leu Arg Leu Arg His Gln Cys Gln Val Asp Thr Pro Phe
195
200
205
Arg Asp Cys Trp Glu Gly Glu Val Asp Leu Val Pro Glu Thr Ser Phe
210
215
220
Glu Phe Lys Phe Val Arg Leu Ile Gly Gly Asp Pro Gln Arg Ala Leu
225
230
235
240
Trp Glu Thr Gly Pro Asn Arg Arg Ala Val Ile Gln Arg Asn Ser Lys
245
250
255
Asp Gly Cys Leu Ile Glu Val Glu Trp Glu Arg Thr Arg Val Leu Phe
260
265
270
Ser Ile Tyr Tyr Pro Thr Lys Glu Lys Gln His Leu Cys Val Thr Gly
275
280
285
Asp Leu Pro Glu Ile Gly Arg Trp Val Glu Pro Gly Pro Val Pro Met
290
295
300
Ala Leu Ser Thr Thr Glu Glu Arg Leu Glu Thr Gly Gly Lys Gly Arg
305
310
315
320
Arg Trp Ser Leu Thr Val Ser Val Pro Ser Thr Val Gly Lys Phe Ala
325
330
335
Tyr Arg Tyr Val Leu Val Asp Asp Asn Arg Gln Gln Thr Ile Trp Glu
340
345
350
Arg Glu Pro Asn Arg Tyr Ala Thr Leu Glu Arg Ala Val Asn Gly Arg
355
360
365
Leu Glu Cys Phe Asp Ala Asn Phe Val Ala Ser Leu Glu Phe Asp Glu
370
375
380
Ile Cys Pro Asp Ile Tyr Ile Gly Pro Tyr Pro Gln Thr Pro Glu His
385
390
395
400
Val Glu Met Met His Glu Ala Gly Ile Thr Ala Val Leu Asn Leu Gln
405
410
415
Thr Asp Glu Asp Phe Ala His Arg Ser Ile Pro Trp Ser Thr Leu Met
420
425
430
Glu Thr Tyr Thr Ala Leu Glu Met Gln Val Ile Arg Cys Pro Ile Pro
435
440
445
Asp Phe Asn Ala Glu Ala Leu Met Gln Leu Leu Pro Asp Ala Val Arg
450
455
460
Ala Leu Asp Ala Ala Leu Lys Ala Lys Arg Val Val Tyr Val His Cys
465
470
475
480
Thr Ala Gly Met Gly Arg Ala Pro Ala Val Val Val Ala Tyr Leu Val
485
490
495
Trp Arg Arg Gly Met Thr Leu Glu Asp Ala Leu Ser His Val Lys Ala
500
505
510
Arg Arg Ala Val Ala Ala Pro Asn Val Thr Val Leu Glu Lys Val Leu
515
520
525
Arg Asn Pro Leu
530

<210>
<211>
<212>
<213>

SEQ ID NO 3
LENGTH, 1521
TYPE, DNA
ORGANISM, Artificial Sequence
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<220> FEATURE,
<223> OTHER INFORMATION, C. merolae laforin Met 27 fragment
<400> SEQUENCE, 3
atggcaagag cgccagctgc tgattcgtct ggtgcgcagt caacaccagc cgcacggcgt

60

gcttccgagg gagtctctgt agctgagcct ccgtcaaagc cagctgctga ttcgtctggt

120

gcgcagtcaa caccagccgc acggcgtgct tccgagggag tctctgtagc tgggcctcca

180

tcaaagccag ctgccgattc gtctggtgcg cagtcaacac cagccgcacg gtttgcatcc

240

gagggtgtct ctgtacctga gcctccgtca aagccagctg ctgattcgtc tggtgcgcag

300

tcaacaccag ccgcacgggg tgcttccgag gatatctctg tacctgggcc tccttcagac

360

attgcggaca cgatctcaaa gaatgatcga agcgtaaccc cgacgattcc gactttattc

420

cgcgtctact gccacacgga gtttggcgat gctgtcgtcg ccgctggtag tcacgacaaa

480

ttgggcaact gggagcccgc gaaagcgctc cggctccgtc atcaatgcca agtggataca

540

ccgttccgtg actgctggga aggcgaggta gaccttgtac ccgaaacaag cttcgagttc

600

aaattcgtgc gtcttatagg cggagatccg cagcgtgcgc tctgggaaac cggacccaac

660

cgaagagccg tgatccagag aaactcgaag gacggctgcc tgattgaagt ggaatgggag

720

cgtacgcgtg tgctgttctc aatatactat cctaccaaag agaagcagca tctctgtgtc

780

actggcgatc ttccggaaat cggtcggtgg gtagaaccgg gtccagtacc catggccctc

840

tcaactactg aggagcgttt ggaaacagga ggcaagggcc gacgttggtc cttgacggtt

900

tcagtgccat ccacggtggg caaattcgcc tatcgctatg tgctagtcga cgataaccgc

960

cagcaaacga tctgggaacg agaaccgaat cgctatgcaa cactagaacg agcggtgaac

1020

gggcgcctcg aatgtttcga tgcaaatttt gtcgcttcgt tagaatttga tgaaatatgt

1080

ccggacattt acatagggcc ctacccacaa actccagagc atgtcgaaat gatgcatgag

1140

gcggggatta cggctgtttt gaatttacag accgatgagg actttgcaca ccgcagtatt

1200

ccctggtcga cgctgatgga gacatataca gcactagaga tgcaagtcat ccgttgtccg

1260

attccggatt ttaatgcgga ggcgctcatg cagttgcttc cggatgccgt acgcgctctt

1320

gatgcggcgc tcaaggcgaa gcgcgtcgtc tacgtgcact gtaccgcagg aatgggtcga

1380

gcgcccgctg tagttgtcgc ctacctcgtg tggcgccgcg gcatgacgct ggaggatgcc

1440

ttgtcgcacg ttaaagcacg tcgtgctgtg gccgcgccga atgtcaccgt attggaaaag

1500

gttcttcgta atcccttgtg a

1521

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 4
LENGTH, 506
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, C. merolae laforin Met 27 polypeptide

<400> SEQUENCE, 4
Met Ala Arg Ala Pro Ala Ala Asp Ser Ser Gly Ala Gln Ser Thr Pro
1
5
10
15
Ala Ala Arg Arg Ala Ser Glu Gly Val Ser Val Ala Glu Pro Pro Ser
20
25
30
Lys Pro Ala Ala Asp Ser Ser Gly Ala Gln Ser Thr Pro Ala Ala Arg
35
40
45
Arg Ala Ser Glu Gly Val Ser Val Ala Gly Pro Pro Ser Lys Pro Ala
50
55
60
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Ala Asp Ser Ser Gly Ala Gln Ser Thr Pro Ala Ala Arg Phe Ala Ser
65

70

75

80

Glu Gly Val Ser Val Pro Glu Pro Pro Ser Lys Pro Ala Ala Asp Ser
85

90

95

Ser Gly Ala Gln Ser Thr Pro Ala Ala Arg Gly Ala Ser Glu Asp Ile
100

105

110

Ser Val Pro Gly Pro Pro Ser Asp Ile Ala Asp Thr Ile Ser Lys Asn
115

120

125

Asp Arg Ser Val Thr Pro Thr Ile Pro Thr Leu Phe Arg Val Tyr Cys
130

135

140

His Thr Glu Phe Gly Asp Ala Val Val Ala Ala Gly Ser His Asp Lys
145

150

155

160

Leu Gly Asn Trp Glu Pro Ala Lys Ala Leu Arg Leu Arg His Gln Cys
165

170

175

Gln Val Asp Thr Pro Phe Arg Asp Cys Trp Glu Gly Glu Val Asp Leu
180

185

190

Val Pro Glu Thr Ser Phe Glu Phe Lys Phe Val Arg Leu Ile Gly Gly
195

200

205

Asp Pro Gln Arg Ala Leu Trp Glu Thr Gly Pro Asn Arg Arg Ala Val
210

215

220

Ile Gln Arg Asn Ser Lys Asp Gly Cys Leu Ile Glu Val Glu Trp Glu
225

230

235

240

Arg Thr Arg Val Leu Phe Ser Ile Tyr Tyr Pro Thr Lys Glu Lys Gln
245

250

255

His Leu Cys Val Thr Gly Asp Leu Pro Glu Ile Gly Arg Trp Val Glu
260

265

270

Pro Gly Pro Val Pro Met Ala Leu Ser Thr Thr Glu Glu Arg Leu Glu
275

280

285

Thr Gly Gly Lys Gly Arg Arg Trp Ser Leu Thr Val Ser Val Pro Ser
290

295

300

Thr Val Gly Lys Phe Ala Tyr Arg Tyr Val Leu Val Asp Asp Asn Arg
305

310

315

320

Gln Gln Thr Ile Trp Glu Arg Glu Pro Asn Arg Tyr Ala Thr Leu Glu
325

330

335

Arg Ala Val Asn Gly Arg Leu Glu Cys Phe Asp Ala Asn Phe Val Ala
340

345

350

Ser Leu Glu Phe Asp Glu Ile Cys Pro Asp Ile Tyr Ile Gly Pro Tyr
355

360

365

Pro Gln Thr Pro Glu His Val Glu Met Met His Glu Ala Gly Ile Thr
370

375

380

Ala Val Leu Asn Leu Gln Thr Asp Glu Asp Phe Ala His Arg Ser Ile
385

390

395

400

Pro Trp Ser Thr Leu Met Glu Thr Tyr Thr Ala Leu Glu Met Gln Val
405

410

415

Ile Arg Cys Pro Ile Pro Asp Phe Asn Ala Glu Ala Leu Met Gln Leu
420

425

430

Leu Pro Asp Ala Val Arg Ala Leu Asp Ala Ala Leu Lys Ala Lys Arg
435

440

445

Val Val Tyr Val His Cys Thr Ala Gly Met Gly Arg Ala Pro Ala Val
450

455

460

Val Val Ala Tyr Leu Val Trp Arg Arg Gly Met Thr Leu Glu Asp Ala
465

470

475

480

Leu Ser His Val Lys Ala Arg Arg Ala Val Ala Ala Pro Asn Val Thr
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485

490

495

Val Leu Glu Lys Val Leu Arg Asn Pro Leu
500
505

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 5
LENGTH, 1140
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, c. merolae laforin Ser157 fragment polypeptide

<400> SEQUENCE,

5

atgtcagtta ccccgaccat cccgacgctg ttccgtgttt attgtcacac cgaatttggc

60

gacgcagttg ttgccgctgg ctcccatgat aaactgggta actgggaacc ggcaaaagct

120

ctgcgtctgc gccatcagtg ccaagttgat accccgttcc gtgactgttg ggaaggcgaa

180

gtggatctgg ttccggaaac gagttttgaa tttaaattcg tccgtctgat tggcggtgac

240

ccgcagcgcg cactgtggga aaccggtccg aaccgtcgcg ctgtgattca acgcaatagc

300

aaagatggct gcctgatcga agttgaatgg gaacgtacgc gcgtcctgtt ttctatctac

360

tacccgacca aagaaaaaca gcacctgtgt gttacgggcg acctgccgga aatcggtcgt

420

tgggtcgaac cgggtccggt gccgatggcg ctgtcaacca cggaagaacg cctggaaacc

480

ggcggtaaag gtcgtcgctg gtcgctgacc gtcagcgtgc cgtctacggt gggcaaattc

540

gcctatcgtt acgttctggt cgatgacaac cgccagcaaa ccatttggga acgtgaaccg

600

aatcgctatg caacgctgga acgtgctgtc aacggtcgcc tggaatgctt cgatgcaaat

660

tttgtggctt ccctggaatt tgatgaaatc tgtccggaca tttatatcgg tccgtacccg

720

cagaccccgg aacatgtgga aatgatgcac gaagcgggca ttaccgccgt tctgaacctg

780

caaacggatg aagacttcgc ccatcgtagt atcccgtggt ccaccctgat ggaaacctac

840

acggcactgg aaatgcaagt gattcgctgc ccgatcccgg attttaatgc ggaagccctg

900

atgcaactgc tgccggatgc agtgcgtgcc ctggacgcag ccctgaaagc aaaacgcgtg

960

gtttatgttc attgtaccgc gggcatgggt cgtgcaccgg ctgtcgtggt tgcgtacctg

1020

gtttggcgtc gcggcatgac gctggaagat gcgctgagcc acgtcaaagc ccgccgtgct

1080

gttgccgccc cgaatgtgac ggtgctggaa aaagttctgc gtaacccgct gtaactcgag

1140

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 6
LENGTH, 377
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, C. merolae laforin Ser157 fragment polypeptide

<400> SEQUENCE,
Met Ser Val Thr Pro Thr Ile Pro Thr Leu Phe Arg Val Tyr Cys His
1
5
10
15
Thr Glu Phe Gly Asp Ala Val Val Ala Ala Gly Ser His Asp Lys Leu
20
25
30
Gly Asn Trp Glu Pro Ala Lys Ala Leu Arg Leu Arg His Gln Cys Gln
35
40
45
Val Asp Thr Pro Phe Arg Asp Cys Trp Glu Gly Glu Val Asp Leu Val
50
55
60
Pro Glu Thr Ser Phe Glu Phe Lys Phe Val Arg Leu Ile Gly Gly Asp
65
70
75
80
Pro Gln Arg Ala Leu Trp Glu Thr Gly Pro Asn Arg Arg Ala Val Ile
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85

90

95

Gln Arg Asn Ser Lys Asp Gly Cys Leu Ile Glu Val Glu Trp Glu Arg
100
105
110
Thr Arg Val Leu Phe Ser Ile Tyr Tyr Pro Thr Lys Glu Lys Gln His
115
120
125
Leu Cys Val Thr Gly Asp Leu Pro Glu Ile Gly Arg Trp Val Glu Pro
130
135
140
Gly Pro Val Pro Met Ala Leu Ser Thr Thr Glu Glu Arg Leu Glu Thr
145
150
155
160
Gly Gly Lys Gly Arg Arg Trp Ser Leu Thr Val Ser Val Pro Ser Thr
165
170
175
Val Gly Lys Phe Ala Tyr Arg Tyr Val Leu Val Asp Asp Asn Arg Gln
180
185
190
Gln Thr Ile Trp Glu Arg Glu Pro Asn Arg Tyr Ala Thr Leu Glu Arg
195
200
205
Ala Val Asn Gly Arg Leu Glu Cys Phe Asp Ala Asn Phe Val Ala Ser
210
215
220
Leu Glu Phe Asp Glu Ile Cys Pro Asp Ile Tyr Ile Gly Pro Tyr Pro
225
230
235
240
Gln Thr Pro Glu His Val Glu Met Met His Glu Ala Gly Ile Thr Ala
245
250
255
Val Leu Asn Leu Gln Thr Asp Glu Asp Phe Ala His Arg Ser Ile Pro
260
265
270
Trp Ser Thr Leu Met Glu Thr Tyr Thr Ala Leu Glu Met Gln Val Ile
275
280
285
Arg Cys Pro Ile Pro Asp Phe Asn Ala Glu Ala Leu Met Gln Leu Leu
290
295
300
Pro Asp Ala Val Arg Ala Leu Asp Ala Ala Leu Lys Ala Lys Arg Val
305
310
315
320
Val Tyr Val His Cys Thr Ala Gly Met Gly Arg Ala Pro Ala Val Val
325
330
335
Val Ala Tyr Leu Val Trp Arg Arg Gly Met Thr Leu Glu Asp Ala Leu
340
345
350
Ser His Val Lys Ala Arg Arg Ala Val Ala Ala Pro Asn Val Thr Val
355
360
365
Leu Glu Lys Val Leu Arg Asn Pro Leu
370
375

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 7
LENGTH, 831
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, C. merolae laforin Gly258 fragment

<400> SEQUENCE, 7
atgggctgcc tgatcgaagt tgaatgggaa cgtacgcgcg tcctgttttc tatctactac

60

ccgaccaaag aaaaacagca cctgtgtgtt acgggcgacc tgccggaaat cggtcgttgg

120

gtcgaaccgg gtccggtgcc gatggcgctg tcaaccacgg aagaacgcct ggaaaccggc

180

ggtaaaggtc gtcgctggtc gctgaccgtc agcgtgccgt ctacggtggg caaattcgcc

240

tatcgttacg ttctggtcga tgacaaccgc cagcaaacca tttgggaacg tgaaccgaat

300

cgctatgcaa cgctggaacg tgctgtcaac ggtcgcctgg aatgcttcga tgcaaatttt

360

gtggcttccc tggaatttga tgaaatctgt ccggacattt atatcggtcc gtacccgcag

420
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accccggaac atgtggaaat gatgcacgaa gcgggcatta ccgccgttct gaacctgcaa

480

acggatgaag acttcgccca tcgtagtatc ccgtggtcca ccctgatgga aacctacacg

540

gcactggaaa tgcaagtgat tcgctgcccg atcccggatt ttaatgcgga agccctgatg

600

caactgctgc cggatgcagt gcgtgccctg gacgcagccc tgaaagcaaa acgcgtggtt

660

tatgttcatt gtaccgcggg catgggtcgt gcaccggctg tcgtggttgc gtacctggtt

720

tggcgtcgcg gcatgacgct ggaagatgcg ctgagccacg tcaaagcccg ccgtgctgtt

780

gccgccccga atgtgacggt gctggaaaaa gttctgcgta acccgctgta a

831

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 8
LENGTH, 276
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, C. merolae laforin Gly258 fragment polypeptide

<400> SEQUENCE, 8
Met Gly Cys Leu Ile Glu Val Glu Trp Glu Arg Thr Arg Val Leu Phe
1
5
10
15
Ser Ile Tyr Tyr Pro Thr Lys Glu Lys Gln His Leu Cys Val Thr Gly
20
25
30
Asp Leu Pro Glu Ile Gly Arg Trp Val Glu Pro Gly Pro Val Pro Met
35
40
45
Ala Leu Ser Thr Thr Glu Glu Arg Leu Glu Thr Gly Gly Lys Gly Arg
50
55
60
Arg Trp Ser Leu Thr Val Ser Val Pro Ser Thr Val Gly Lys Phe Ala
65
70
75
80
Tyr Arg Tyr Val Leu Val Asp Asp Asn Arg Gln Gln Thr Ile Trp Glu
85
90
95
Arg Glu Pro Asn Arg Tyr Ala Thr Leu Glu Arg Ala Val Asn Gly Arg
100
105
110
Leu Glu Cys Phe Asp Ala Asn Phe Val Ala Ser Leu Glu Phe Asp Glu
115
120
125
Ile Cys Pro Asp Ile Tyr Ile Gly Pro Tyr Pro Gln Thr Pro Glu His
130
135
140
Val Glu Met Met His Glu Ala Gly Ile Thr Ala Val Leu Asn Leu Gln
145
150
155
160
Thr Asp Glu Asp Phe Ala His Arg Ser Ile Pro Trp Ser Thr Leu Met
165
170
175
Glu Thr Tyr Thr Ala Leu Glu Met Gln Val Ile Arg Cys Pro Ile Pro
180
185
190
Asp Phe Asn Ala Glu Ala Leu Met Gln Leu Leu Pro Asp Ala Val Arg
195
200
205
Ala Leu Asp Ala Ala Leu Lys Ala Lys Arg Val Val Tyr Val His Cys
210
215
220
Thr Ala Gly Met Gly Arg Ala Pro Ala Val Val Val Ala Tyr Leu Val
225
230
235
240
Trp Arg Arg Gly Met Thr Leu Glu Asp Ala Leu Ser His Val Lys Ala
245
250
255
Arg Arg Ala Val Ala Ala Pro Asn Val Thr Val Leu Glu Lys Val Leu
260
265
270
Arg Asn Pro Leu

275
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<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 9
LENGTH, 801
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, C. merolae laforin Arg267 fragment

<400> SEQUENCE, 9
cgtacgcgcg tcctgttttc tatctactac ccgaccaaag aaaaacagca cctgtgtgtt

60

acgggcgacc tgccggaaat cggtcgttgg gtcgaaccgg gtccggtgcc gatggcgctg

120

tcaaccacgg aagaacgcct ggaaaccggc ggtaaaggtc gtcgctggtc gctgaccgtc

180

agcgtgccgt ctacggtggg caaattcgcc tatcgttacg ttctggtcga tgacaaccgc

240

cagcaaacca tttgggaacg tgaaccgaat cgctatgcaa cgctggaacg tgctgtcaac

300

ggtcgcctgg aatgcttcga tgcaaatttt gtggcttccc tggaatttga tgaaatctgt

360

ccggacattt atatcggtcc gtacccgcag accccggaac atgtggaaat gatgcacgaa

420

gcgggcatta ccgccgttct gaacctgcaa acggatgaag acttcgccca tcgtagtatc

480

ccgtggtcca ccctgatgga aacctacacg gcactggaaa tgcaagtgat tcgctgcccg

540

atcccggatt ttaatgcgga agccctgatg caactgctgc cggatgcagt gcgtgccctg

600

gacgcagccc tgaaagcaaa acgcgtggtt tatgttcatt gtaccgcggg catgggtcgt

660

gcaccggctg tcgtggttgc gtacctggtt tggcgtcgcg gcatgacgct ggaagatgcg

720

ctgagccacg tcaaagcccg ccgtgctgtt gccgccccga atgtgacggt gctggaaaaa

780

gttctgcgta acccgctgta a

801

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 10
LENGTH, 267
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, C. merolae laforin Arg267 fragment polypeptide

<400> SEQUENCE, 10
Met Arg Thr Arg Val Leu Phe Ser Ile Tyr Tyr Pro Thr Lys Glu Lys
1
5
10
15
Gln His Leu Cys Val Thr Gly Asp Leu Pro Glu Ile Gly Arg Trp Val
20
25
30
Glu Pro Gly Pro Val Pro Met Ala Leu Ser Thr Thr Glu Glu Arg Leu
35
40
45
Glu Thr Gly Gly Lys Gly Arg Arg Trp Ser Leu Thr Val Ser Val Pro
50
55
60
Ser Thr Val Gly Lys Phe Ala Tyr Arg Tyr Val Leu Val Asp Asp Asn
65
70
75
80
Arg Gln Gln Thr Ile Trp Glu Arg Glu Pro Asn Arg Tyr Ala Thr Leu
85
90
95
Glu Arg Ala Val Asn Gly Arg Leu Glu Cys Phe Asp Ala Asn Phe Val
100
105
110
Ala Ser Leu Glu Phe Asp Glu Ile Cys Pro Asp Ile Tyr Ile Gly Pro
115
120
125
Tyr Pro Gln Thr Pro Glu His Val Glu Met Met His Glu Ala Gly Ile
130
135
140
Thr Ala Val Leu Asn Leu Gln Thr Asp Glu Asp Phe Ala His Arg Ser
145
150
155
160
Ile Pro Trp Ser Thr Leu Met Glu Thr Tyr Thr Ala Leu Glu Met Gln
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165

170

175

Val Ile Arg Cys Pro Ile Pro Asp Phe Asn Ala Glu Ala Leu Met Gln
180

185

190

Leu Leu Pro Asp Ala Val Arg Ala Leu Asp Ala Ala Leu Lys Ala Lys
195
200
205

Arg Val Val Tyr Val His Cys Thr Ala Gly Met Gly Arg Ala Pro Ala
210

215

220

Val Val Val Ala Tyr Leu Val Trp Arg Arg Gly Met Thr Leu Glu Asp
225

230

235

240

Ala Leu Ser His Val Lys Ala Arg Arg Ala Val Ala Ala Pro Asn Val
245

250

255

Thr Val Leu Glu Lys Val Leu Arg Asn Pro Leu
260

265

What is claimed is:
1. A non-native glucan phosphatase polypeptide comprising the amino acid sequence as set forth in SEQ ID NO: 6, 8
or 10.
2. The polypeptide of claim 1, wherein the polypeptide is a
thermophile.
3. The polypeptide of claim 2, wherein the polypeptide is
stable at least at a 3.0 pH to about 8.0 pH.
4. The polypeptide of claim 2, wherein the polypeptide is
stable at least at a temperature of about 10° C. to about 75° C.

20

25

5. A method for processing starch, comprising:
providing the thermophilic glucan phosphatase of claim 1;
exposing a starch to the thermophilic glucan phosphatase;
and
collecting the starch that has been exposed to the thermophilic glucan phosphatase.
6. The method of claim 5, further comprising, before the
collecting step, exposing the starch to a kinase, an amylase, or
both.

* * * * *

